Glaxo Group Limited

Smithkline Beecham Corporation

Sanofi

Glaxo Wellcome Inc.

Colin David Eldred

Andrew Michael Kenneth Pennell

Stephen Swanson

David E Bays

Duncan B Judd

Lee Andrew Harrison

Suzanne Elaine Keeling

Xiao Qing Lewell

Simon Teanby Hodgson

Caroline Mary Cook

Paul Martin Gore

Graeme Michael Robertson

Alexander W Oxford

Ian H Coates

Hazel Joan Dyke

Michael D Dowle

Barry C Ross

David Middlemiss

Brian Cox

Pritom Shah

Richard Peter Charles Cousins

Martin Pass

John G Montana

Rachael Anne Ancliff

Brian David Judkins

Richard Peter Charles

Julie Nicole Hamblin

David C Humber

George B Ewan

Paul Spencer Jones

Thomas Daniel Heightman

William L Mitchell

Stephen Barry Guntrip

James A Bell

Michael David Barker

David I Scopes

Simon John Fawcett MacDonald

Alison Judith Redgrave

Jag Paul Heer

Brian Evans

Christopher James Lunniss

Stephen Paul Watson

Frank Ellis

Hailong Wang

David George Allen

Graham George Adam Inglis

Colin F Webb

David House

Ian Robert Baldwin

Kevin S Cardwell

Keith Mills

Torquil I Jack

Michael David Woodrow

John Edward Robinson

John Skidmore

Philip Alan Skone

Anthony William Dean

Stuart Holman

Andrew Michael Pennell

Andrew John Walker

Mark Wilkinson

Rachael Ann Ancliff

Martin Alistair Hayes

Gail Mills

Tracy Jane Redfern

Mika Kristian Lindvall

Sharon Lisa Gough

The present invention relates to novel oxadiazole derivatives having pharmacological activity, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of various disorders.

Compounds

Indazoles as glucocorticoid receptor ligands

Morpholinyl-urea derivatives for use in the treatment of inflammatory diseases

There are provided according to the invention novel compounds of formula (I)  or pharmaceutically acceptable salts thereof, wherein R, RRRand Rare as described in the specification, processes for preparing them, formulations containing them and their use in therapy for the treatment of inflammatory diseases.

Quinoline derivatives as phosphodiesterase inhibitors

There are provided according to the invention, novel compounds of formula (I) wherein R, R, R, R, R, R, X, a, b and Z are as defined in the specification, processes for preparing them, formulations containing them and their use in therapy for the treatment of inflammatory diseases.

Compounds useful in the treatment of inflammatory diseases

The present invention relates to novel morpholin-acetamide compounds of formula (I) useful for the treatment of inflammatory diseases. Compounds of formula (I)wherein R, R, R, R, R, X, a, b and Z are as defined in the specification, processes for preparing them, formulations containing them and their use in therapy for the treatment of inflammatory diseases.

Morpholin-acetamide derivatives for the treatment of inflammatory diseases

A compound of formula (I), wherein R represents C alkyl, halogen or hydrogen; R represents straight or branched alkyl group of 1-6 carbon atoms; with the proviso that, when R represents C alkyl, R represents C alkyl, R cannot represent phenyl optionally substituted by one or more substituents selected from halogen, C alkyl, trifluoromethyl, nitro, cyano, &mdash;CO R , &mdash;CONR R , &mdash;COR , &mdash;SOR , &mdash;SO R , &mdash;SO H, &mdash;SO NR R , &mdash;OR , &mdash;NHSO R , &mdash;NHCOR and &mdash;NR R ; and salts and solvates thereof, in particular, physiologically acceptable solvates and salts thereof. These compounds are agonists at the Adenosine A1 receptor.

Chemical compounds

A method of treating a patient suffering from or susceptible to ischemic heart disease, peripheral vascular disease or stroke or which subject is suffering pain, a CNS disorder or sleep apnea which comprises administering a therapeutically effective amount of an adenosine derivative which is an agonist at the adenosine A1 receptor and which exhibits little or no agonist activity of the A3 receptor. The adenosine derivative has a general formula (I) as follows:

Adenosine derivatives and methods of administration

A compound of formula (I), wherein R represents C alkyl, halogen or hydrogen; R represents straight or branched alkyl group of 1-6 carbon atoms; with the proviso that, when R represents C alkyl, R represents C alkyl, R cannot represent phenyl optionally substituted by one or more substituents selected from halogen, C alkyl, trifluoromethyl, nitro, cyano, &mdash;CO R , &mdash;CONR R , &mdash;COR , &mdash;SOR , SO R , &mdash;SO H, &mdash;SO NR R , &mdash;OR , &mdash;NHSO R , &mdash;NHCOR and &mdash;NR R ; and salts and solvates thereof, in particular, physiologically acceptable solvates and salts thereof. These compounds are agonists at the Adenosine Al receptor.

A compound of formula (I) which is an agonist at the adenosine Al receptor, wherein Y, Z, and W represent heteroatoms, and salts and solvates thereof, in particular, physiologically acceptable solvates and salts thereof for use in therapy.

Adenosine derivatives

A compound of formula (I) which is an agonist at the adenosine A1 receptor wherein R represents C alkyl, halogen or hydrogen; R represents a fluorinated straight or branched alkyl group of 1-6 carbon atoms and salts and solvates thereof, in particular, physiologically acceptable solvates and salts thereof. These compounds are agonists at the adenosine A1 receptor.

Chemical Compounds

Piperidineacetic acid derivatives useful as fibrinogen antagonist agent

The invention provides compounds of the general formula (I): ##STR1## or a physiologically acceptable salt, solvate (e.g. hydrate) or a metabolically labile ester thereof. The compounds may be used in the treatment or prophylaxis of hypertension and diseases associated with cognitive disorders.

C-linked pyrazole derivatives

The invention provides compounds of formula (I): ##STR1## or a physiologically acceptable salt, solvate or metabolically labile ester thereof. The compounds may be used in the treatment or prophylaxis of hypertension and diseases associated with cognitive disorders.

Pyrazole containing benzofuran derivatives and pharmaceutical

Growing community of inventors

Stevenage, United Kingdom

Colin David Eldred